To the full analysis
Castle Biosciences stock: growth
CSTLCastle Biosciences reported $344.23M in revenue for fiscal 2025, up 3.7% on the prior year, up 40.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
49.6%
per year from 2017 to 2025, per share 30.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 40.6% | 49.6% |
| Revenue per share | 29.1% | 30.6% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | 40.8% | no data |
| Free cash flow per share | 29.3% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $13.75M | −$12.37M | −$12.73M |
| 2018 | $22.79M | −$6.37M | −$12.57M |
| 2019 | $51.87M | $5.28M | $6.08M |
| 2020 | $62.65M | −$10.28M | $5.11M |
| 2021 | $94.09M | −$31.29M | −$22.47M |
| 2022 | $137.04M | −$67.14M | −$47.29M |
| 2023 | $219.79M | −$57.47M | −$19.25M |
| 2024 | $332.07M | $18.25M | $36.54M |
| 2025 | $344.23M | −$24.16M | $28.33M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.